Abstract Introduction Premature ejaculation (PE) is the most prevalent male sexual dysfunction, significantly affecting the quality of life of both affected individuals and their partners. It is defined by ejaculation occurring earlier than desired, either before or shortly after vaginal penetration. PE is traditionally classified into lifelong and acquired, with distinct diagnostic criteria introduced by the International Society for Sexual Medicine (ISSM), the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and the International Classification of Diseases, 11th Revision (ICD-11). Current treatment options include pharmacological therapies such as SSRIs, topical anesthetics, behavioral therapies, pelvic floor exercises, and sexual psychotherapy with a partner. In recent years, surgical interventions such as glans augmentation, dorsal nerve neurectomy, and botulinum toxin injections into the bulbospongiosus muscle have garnered increasing interest as promising treatment modalities. Although numerous therapeutic options are available, there remains no consensus on their optimal application, sequencing, or combination in clinical practice. The growing interest in surgical treatments further underscores the variability in PE management strategies. This study aims to fill these gaps by evaluating clinicians’ practices in diagnosing and managing PE, focusing on treatment patterns and the use of innovative therapies, through a comprehensive nationwide survey in Turkey. Objective This study aimed to evaluate the diagnostic and therapeutic approaches to premature ejaculation (PE), focusing on variations in clinical practices and guideline adherence. Methods A structured survey was anonymously distributed via Google Forms to 900 clinicians between April 30 and June 10,2024, of whom 378 completed the questionnaire, yielding a response rate of 42%. Participants included urologists, andrologists, psychiatrists, and sexual psychotherapists. The questionnaire covered diagnostic criteria, laboratory investigations, treatment preferences, management strategies for comorbid conditions, along with attitudes toward behavioral and invasive interventions. Statistical analyses included descriptive statistics, chi-square, and Fisher’s exact tests. Results The study revealed marked variability in the diagnosis and treatment of PE. While the ISSM definition was the most commonly used guideline (40.5%), psychiatrists predominantly relied on DSM-5-TR criteria (88.2%). Laboratory testing, including testosterone and thyroid function evaluations, was employed by 54.2% of participants. Dapoxetine was the most preferred first-line therapy (31.2%), followed by behavioral therapies (20.6%) and local anesthetics (19.6%). For patients unresponsive to initial therapies, couple-based sexual psychotherapy (18.6%) and use of long-acting daily SSRIs (14.8%) were the most preferred second-line treatments. Combination therapies were widely adopted (89.1%), though their components varied significantly. Surgical and invasive treatments, such as hyaluronic acid injections, were rarely utilized (18.3%), with most physicians reserving them for refractory cases. Pelvic floor relaxation exercises were recommended by 72% of participants, while 87.5% endorsed behavioral therapies for PE. Conclusions This study revealed substantial variability in PE management, its multifaceted etiology and guideline limitations. The findings underscore the need for standardized, evidence-based protocols to enhance clinical outcomes and optimize patient satisfaction. Disclosure No
Cinar et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: